A study on RPGR gene correction elucidates that PR loss can be reversed in retinal organoids derived from RP patient-specific iPSCs [101], which recapitulate disease pathology due to the RPGR mutation and can be used for drug screening [101]. The gene discussed is RPGR; the disease is retinitis pigmentosa 1.